Related Experiment Video

Updated: Apr 14, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after

Jia-Hui Zhang1, Jing Wang1, Xiao-Fang Tang1

  • 1a Department of Cardiology, State Key Laboratory of Cardiovascular Disease , Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , People's Republic of China.

Platelets
|April 23, 2015
PubMed

Insights

Genetic variations in platelet receptors impact cardiovascular event risk. Specific F2R and P2RY12 gene variants predict ischemic and bleeding events, respectively, in ST-elevation myocardial infarction patients post-percutaneous coronary intervention.

Area of Science:

  • Cardiovascular Genetics
  • Pharmacogenomics
  • Thrombosis Research

Background:

  • Platelet receptor gene polymorphisms can alter platelet function.
  • Understanding these genetic influences is crucial for managing patients undergoing percutaneous coronary intervention (PCI).

Purpose of the Study:

  • To investigate the association between five platelet receptor gene polymorphisms and the risk of ischemic and bleeding events.
  • To assess the predictive value of these polymorphisms in ST-elevation myocardial infarction (STEMI) patients treated with dual antiplatelet therapy post-PCI.

Main Methods:

  • A cohort of 503 STEMI patients post-PCI were genotyped for ITGA2, GP6, F2R, and P2RY12 polymorphisms.
  • Patients received standard dual antiplatelet therapy for 12 months, with follow-up for ischemic and bleeding events.
  • Multivariate Cox and logistic regression analyses were used to determine independent predictors of adverse events, with validation in a second cohort of 483 patients.

Main Results:

  • The F2R rs168753 minor allele was an independent predictor of composite ischemic events (HR 0.387, p=0.008).
  • The P2RY12 rs6809699 minor allele independently predicted major bleedings (OR 2.71, p=0.008).
  • These findings were validated in an independent cohort.

Conclusions:

  • F2R rs168753 minor allele carriage is associated with a reduced risk of ischemic events.
  • P2RY12 rs6809699 minor allele carriage is associated with an increased risk of bleeding events.
  • Genetic testing of platelet receptors may aid in predicting adverse outcomes in STEMI patients post-PCI.

Keywords:
Clinical outcomesSTEMIplatelet receptor genepolymorphism

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

2.2K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
151
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.9K